This study is testing whether a drug called baricitinib can help preserve the body's ability to make insulin (beta-cell function) in children and adults who have been recently diagnosed with type 1 diabetes. Participants will receive either baricitinib or a placebo (an inactive substance) orally. We're looking to see if there's a change in C-peptide (a measure of insulin production) after 52 weeks. You may be able to join if you are between 1 and 35 years old, were diagnosed with type 1 diabetes within the last 100 days, have certain diabetes-related autoantibodies, and show signs of remaining beta-cell function. The study aims to enroll 300 participants, but its current status is unclear.

Study design

This interventional study will involve about 300 participants. It compares baricitinib to a placebo, both given orally.

What's involved

Participation in the study will last about 60 weeks. Your C-peptide levels will be measured at the beginning and again at Week 52.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint for measuring C-peptide change is at Week 52.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.